Peter A. Thompson
Peter A. Thompson's purchase track record
How the stock did after each of Peter A. Thompson's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/3/2025 | EWTX | $10.00M | -4.0% | +10.5% | +24.4% |
| 2/10/2025 | SION | $9.90M | -42.0% | -9.9% | +5.1% |
| 1/23/2024 | EWTX | $5.00M | +1.2% | +40.9% | +14.2% |
| 8/29/2023 | SPRY | $3.10M | -32.1% | +24.4% | +12.9% |
| 9/16/2022 | EWTX | $5.00M | -17.1% | -21.0% | +1.1% |
| 5/18/2022 | EWTX | $995K | +47.3% | +37.5% | +0.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Corvus Pharma Q2 2026 Earnings Call Transcript Released. Corvus Pharmaceuticals released the transcript of its Q2 2026 earnings call. The document offers details on the company’s recent financial results and guidance for the upcoming period. Investors can review the call to better understand the company’s performance and strategic priorities.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Edgewise Therapeutics Doses First Patient in Phase 2 Trial. Edgewise Therapeutics has dosed the first participant in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, a drug intended to treat heart failure with preserved ejection fraction. This marks a key clinical milestone for the company. The stock is currently trading near its 52-week high, with analysts maintaining an average price target of $52.62.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Aquestive news highlights biotech valuation dynamics. Recent market discussion focused on Aquestive Therapeutics and the pricing of anaphylaxis drug success. While this news does not directly involve ARS Pharmaceuticals, it reflects broader sector sentiment regarding biotech valuations. ARS Pharmaceuticals is currently trading with an RSI of 37.5, indicating mild oversold conditions relative to its recent range.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Janux Therapeutics Faces Uncertainty Over Prostate Cancer Program. The company said it is still early to determine if its prostate cancer program will succeed. This uncertainty may weigh on the stock as investors assess the program’s progress. The shares are near a key support level, adding to the caution.
Transaction History
| SION | ▼ Sell | Open Market | 85,918 | $3.9M | 7/7/2026 | View on chart |
| SION | ▼ Sell | Open Market | 115,844 | $5.3M | 6/30/2026 | View on chart |
| SION | ▼ Sell | Open Market | 101 | $4K | 5/27/2026 | View on chart |
| SION | ▼ Sell | Open Market | 184,639 | $8.5M | 5/11/2026 | View on chart |
| SION | ▼ Sell | Open Market | 59,767 | $2.7M | 5/8/2026 | View on chart |
| SION | ▼ Sell | Open Market | 48,546 | $2.2M | 5/7/2026 | View on chart |
| SION | ▼ Sell | Open Market | 2,948 | $131K | 4/18/2026 | View on chart |
| SION | ▼ Sell | Open Market | 52,397 | $2.3M | 4/17/2026 | View on chart |
| SION | ▼ Sell | Open Market | 226,906 | $10.3M | 4/16/2026 | View on chart |
| SION | ▼ Sell | Open Market | 235,863 | $10.5M | 4/15/2026 | View on chart |
| SION | ▼ Sell | Open Market | 47,814 | $2.1M | 4/14/2026 | View on chart |
| SION | ▼ Sell | Open Market | 29,063 | $1.3M | 2/3/2026 | View on chart |
| SION | ▼ Sell | Open Market | 1,890 | $84K | 2/2/2026 | View on chart |
| CRVS | ▲ Buy | Option Exercise | 30,000 | $450K | 1/28/2026 | View on chart |
| CRVS | ▲ Buy | Option Exercise | 15,000 | $146K | 1/28/2026 | View on chart |
| CRVS | ▲ Buy | Option Exercise | 15,000 | $188K | 1/28/2026 | View on chart |
| CRVS | ▲ Buy | Option Exercise | 15,000 | $54K | 1/28/2026 | View on chart |
| CRVS | ▲ Buy | Option Exercise | 15,000 | $30K | 1/28/2026 | View on chart |
| CRVS | ▲ Buy | Option Exercise | 15,000 | $49K | 1/28/2026 | View on chart |
| CRVS | ▲ Buy | Option Exercise | 15,000 | $41K | 1/28/2026 | View on chart |
| CRVS | ▲ Buy | Option Exercise | 15,000 | $39K | 1/28/2026 | View on chart |
| CRVS | ▲ Buy | Option Exercise | 15,000 | $15K | 1/28/2026 | View on chart |
| CRVS | ▲ Buy | Option Exercise | 15,000 | $14K | 1/28/2026 | View on chart |
| CRVS | ▲ Buy | Option Exercise | 15,000 | $37K | 1/28/2026 | View on chart |
| CRVS | ▲ Buy | Option Exercise | 15,000 | $25K | 1/28/2026 | View on chart |
| CRVS | ▲ Buy | Option Exercise | 15,000 | $32K | 1/28/2026 | View on chart |
| SION | ▼ Sell | Open Market | 33,356 | $1.5M | 12/24/2025 | View on chart |
| SION | ▼ Sell | Open Market | 875 | $39K | 12/19/2025 | View on chart |
| SION | ▼ Sell | Open Market | 100 | $4K | 12/18/2025 | View on chart |
| SION | ▼ Sell | Open Market | 900 | $40K | 12/17/2025 | View on chart |
| SION | ▼ Sell | Open Market | 1,600 | $71K | 11/26/2025 | View on chart |
| SION | ▼ Sell | Open Market | 11,890 | $530K | 11/25/2025 | View on chart |
| SION | ▼ Sell | Open Market | 94,583 | $4.2M | 11/24/2025 | View on chart |
| CRVS | ▼ Sell | Other | 1,397,684 | $4.9M | 6/27/2025 | View on chart |
| CRVS | ▼ Sell | Open Market | 1,176,332 | $4.9M | 6/27/2025 | View on chart |
| EWTX | ▲ Buy | Open Market | 372,578 | $7.5M | 4/3/2025 | View on chart |
| EWTX | ▲ Buy | Open Market | 124,193 | $2.5M | 4/3/2025 | View on chart |
| SION | ▲ Buy | Open Market | 550,000 | $9.9M | 2/10/2025 | View on chart |
| SION | ▼ Sell | Other | 3,154,959 | — | 2/10/2025 | View on chart |
| SPRY | ▼ Sell | Open Market | 83,695 | $1.1M | 8/26/2024 | View on chart |
| SPRY | ▼ Sell | Open Market | 69,500 | $906K | 8/23/2024 | View on chart |
| SPRY | ▼ Sell | Open Market | 391,482 | $5.1M | 8/22/2024 | View on chart |
| SPRY | ▼ Sell | Open Market | 394,400 | $5.3M | 8/21/2024 | View on chart |
| SPRY | ▼ Sell | Open Market | 13,300 | $194K | 8/21/2024 | View on chart |
| EWTX | ▲ Buy | Open Market | 454,545 | $5.0M | 1/23/2024 | View on chart |
| SPRY | ▲ Buy | Open Market | 500,000 | $3.1M | 8/29/2023 | View on chart |
| EWTX | ▲ Buy | Open Market | 484,496 | $5.0M | 9/16/2022 | View on chart |
| EWTX | ▲ Buy | Open Market | 138,000 | $995K | 5/18/2022 | View on chart |
| JANX | ▼ Sell | Open Market | 3,700 | $75K | 12/29/2021 | View on chart |
| JANX | ▼ Sell | Open Market | 36,700 | $745K | 12/29/2021 | View on chart |
| JANX | ▼ Sell | Open Market | 108,300 | $2.1M | 12/21/2021 | View on chart |
| JANX | ▼ Sell | Open Market | 11,100 | $211K | 12/21/2021 | View on chart |
| JANX | ▼ Sell | Open Market | 356,800 | $6.8M | 12/16/2021 | View on chart |
| JANX | ▼ Sell | Open Market | 36,500 | $696K | 12/16/2021 | View on chart |
| CRVS | ▼ Sell | Open Market | 1,109,644 | $6.8M | 9/20/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Sionna Shares Fall 37.6% Over 4 Weeks, Trend Reversal Possible
Sionna Therapeutics shares fell 37.6% over the past four weeks. The drop has pushed the stock into a low RSI zone of 23.4, suggesting it may be oversold. The price is near a key support level at $5.71, which has been tested 20 times. Analysts see a potential trend reversal, but the stock remains far below its 52‑week high of $54.97.
Sionna Shares Fall 37.6% Over 4 Weeks, Trend Reversal Possible. Sionna Therapeutics shares fell 37.6% over the past four weeks. The drop has pushed the stock into a low RSI zone of 23.4, suggesting it may be oversold. The price is near a key support level at $5.71, which has been tested 20 times. Analysts see a potential trend reversal, but the stock remains far below its 52‑week high of $54.97.